BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27377091)

  • 1. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: A narrative review.
    Damiano R; Cai T; Fornara P; Franzese CA; Leonardi R; Mirone V
    Arch Ital Urol Androl; 2016 Jul; 88(2):136-43. PubMed ID: 27377091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study.
    Vahlensieck W; Theurer C; Pfitzer E; Patz B; Banik N; Engelmann U
    Urol Int; 2015; 94(3):286-95. PubMed ID: 25196580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial.
    Zerafatjou N; Amirzargar M; Biglarkhani M; Shobeirian F; Zoghi G
    BMC Urol; 2021 Oct; 21(1):147. PubMed ID: 34666728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study.
    Theil G; Richter M; Schulze M; Köttig T; Patz B; Heim S; Krauß Y; Markov M; Fornara P
    World J Urol; 2022 Jul; 40(7):1769-1775. PubMed ID: 35622117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
    Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.
    Cicero AFG; Allkanjari O; Busetto GM; Cai T; Larganà G; Magri V; Perletti G; Robustelli Della Cuna FS; Russo GI; Stamatiou K; Trinchieri A; Vitalone A
    Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
    Jhang JF; Liao CH; Kuo HC
    Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do we really need herbal medicine in LUTS/BPH treatment in the 21
    Pinggera GM; Frauscher F
    Expert Opin Drug Saf; 2016 Dec; 15(12):1573-1575. PubMed ID: 27461908
    [No Abstract]   [Full Text] [Related]  

  • 16. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
    Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    De Nunzio C; Salonia A; Gacci M; Ficarra V
    World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
    Yuan RQ
    Zhonghua Nan Ke Xue; 2012 Dec; 18(12):1147-51. PubMed ID: 23405801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising molecular targets and biomarkers for male BPH and LUTS.
    Gharaee-Kermani M; Macoska JA
    Curr Urol Rep; 2013 Dec; 14(6):628-37. PubMed ID: 23913202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.